Celltrion to supply Remsima, Herzuma to Peru

The company's autoimmune disease treatment and breast cancer biosimilar won a Peruvian government tender

Celltrion's Remsima (Courtesy of Celltrion)
Celltrion's Remsima (Courtesy of Celltrion)
Jeong Min Nam 1
2024-05-02 16:27:08 peux@hankyung.com
Bio & Pharma

South Korea's Celltrion Inc. announced on Thursday that it secured a contract to supply its biosimilars for autoimmune disease treatment and anticancer drugs in Peru.

According to the company, its biosimilar for autoimmune disease treatment Remsima (infliximab) was awarded in a bid by Seguro Social de Salud (EsSalud) in Peru. It will be supplied for one year starting this month. 

The company explained that this bid accounted for 81% of the total volume of infliximab-based treatments in Peru.

Celltrion's Herzuma 
Celltrion's Herzuma 

Celltrion's anticancer biosimilar Herzuma (trastuzumab) for breast and gastric cancers won a supply contract through a bid by the Peruvian Ministry of Health and will be supplied for one year starting from July.

The company will supply four products to Peru, including the blood cancer treatment Truxima (rituximab) and the autoimmune disease treatment Yuflyma (adalimumab), awarded in bids by Peruvian public institutions in February.

The anticancer drug Vegzelma (bevacizumab) is scheduled to be launched in Peru this month.

Write to Jeong Min Nam at peux@hankyung.com
#Celltrion #Remsima #EsSalud #infliximab #Herzuma #Truxima #Yuflyma #Vegzelma

Celltrion releases Remsima SC in Denmark

Celltrion releases Remsima SC in Denmark

South Korea's Celltrion Inc. announced on Thursday that it released its autoimmune disease treatment Remsima SC (infliximab) in Denmark. Remsima SC is a subcutaneous (SC) formulation of the autoimmune disease treatment Remsima, containing the ingredient infliximab. It obtained a new drug

Korea’s Celltrion, SK Biopharmaceuticals benefit from direct US sales

Korea’s Celltrion, SK Biopharmaceuticals benefit from direct US sales

Celltrion is a leading South Korean biopharmaceutical company Celltrion Inc. and SK Biopharmaceuticals Co. are witnessing improving sales revenue and profitability by selling their products through their own marketing channels instead of using local sales partners in the US market.Celltrion, a

Celltrion'a autoimmune disease drug Zymfentra makes US debut

Celltrion'a autoimmune disease drug Zymfentra makes US debut

Celltrion headquarters in Incheon, South Korea South Korean biopharmaceutical giant Celltrion Inc. said on March 17 that it has launched its new autoimmune disease treatment Zymfentra in the US market. The drug is a subcutaneous injection of Celltrion’s infliximab Remsima, a treatment for

Celltrion ships initial supply of Zymfentra to US

Celltrion ships initial supply of Zymfentra to US

Celltrion's Zymfentra South Korea's Celltrion Inc. announced on Wednesday that it shipped the first supply of its subcutaneous injection type of the autoimmune disease treatment Remsima SC (active ingredient infliximab, American name Zymfentra) to the US. The completed product shipped toda

Celltrion to deliver three treatments to Peru

Celltrion to deliver three treatments to Peru

South Korea’s Celltrion Inc. announced on Thursday that it will supply three treatments, including its blood cancer drug Truxima (rituximab) to Peru. Celltrion's Truxima secured an order in tenders conducted by both the Peruvian Ministry of Health (CENARES) and Peru Social Health Insura
(* comment hide *}